Business Wire

Germany’s Largest Public Insurer Versicherungskammer Selects Clearwater Analytics for Scalable Investment Operations

2.7.2025 10:00:00 EEST | Business Wire | Press release

Share

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Versicherungskammer Group has selected Clearwater Analytics’ platform to power their middle, back office and risk functions.

This decision is based on a comprehensive operating model review that began in 2024, followed by a structured selection process to identify a strategic partner. The rigorous assessment underscored the need for change, as market developments and demographic shifts demanded more agility, transparency, and efficiency. By adopting Clearwater’s modern, cloud-based platform, Versicherungskammer will gain real-time, advanced data analytics to strengthen investment decision-making and drive improved performance. This will allow Versicherungskammer to focus on its core competencies in capital investment in the future.

“Partnering with Clearwater marks an important shift in our investment operations strategy and is central to our goal of future-proofing Versicherungskammer’s investment capabilities,” said Martin Knobbe, Head of Middle and Back Office Investment at Versicherungskammer. “Versicherungskammer becomes part of a platform with over 700 insurance customers, which offers considerable network advantages. This partnership allows us to focus on our core competencies, enhances data quality, supports our decision-making processes, and lays the foundations for the further development of our risk and performance management. This transition not only improves agility and flexibility of our business processes - it future-proofs the Group’s investment operations and provides us with economic advantages.”

“Versicherungskammer is setting a new benchmark for insurers modernizing their investment operations,” said Keith Viverito, Managing Director EMEA at Clearwater Analytics. “It’s a privilege to partner with them on this transformation. Together, we’re implementing a solution that combines technology from our recent acquisitions, Enfusion and Beacon, to deliver a powerful front-to-back platform. This will modernize Versicherungskammer’s operations, significantly enhance the accuracy and timeliness of their data across all asset classes, and support their long-term growth objectives.”

Versicherungskammer joins more than 2,400 clients worldwide on Clearwater’s unique single-instance, multi-tenant platform. The solution delivers comprehensive investment data management, risk, performance, accounting, and reporting capabilities through a single, unified cloud-native system that eliminates data silos and automates manual processes that impact efficiency and accuracy.

Contact an expert today for more information about Clearwater Analytics and how our solutions can support your organization.

About Versicherungskammer Bayern

The Versicherungskammer Group is the largest public insurer in Germany and is among the top 10 primary insurers in Germany. With its regionally active companies, the company is active in Bavaria, the Palatinate, Saarland as well as in Berlin and Brandenburg. The health insurer of the S-Finanzgruppe operates nationwide together with the other public insurers. The social commitment of the Versicherungskammer Group is of great importance. The sustainability-oriented strategy of promoting voluntary institutions and initiatives, which are particularly active in the field of prevention and safety, has been further strengthened for several years by the two foundations, the Versicherungskammer-Stiftung and Versicherungskammer-Kulturstiftung. In addition, the Versicherungskammer Group has been awarded the “Work and Family” certificate as a family-friendly company for the third time. It has around 7,500 employees, including around 340 trainees. Further information can be found at Konzern Versicherungskammer | VK Konzernportal.

About Clearwater Analytics

Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $8.8 trillion in assets globally. Learn more at www.clearwateranalytics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702949429/en/

Contacts

Media Contact:
Claudia Cahill, Head of Communications and PR | +1 208-433-1200 |
press@clearwateranalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye